Jubilant Ingrevia Ltd

Jubilant Ingrevia Limited reported strong financial performance in Q2 and H1 FY27, with revenue growing 24% year-on-year to INR1,394 crore and EBITDA increasing 51% to INR221 crore. Management highlighted disciplined execution across businesses, including a 24% revenue growth in Acetyls and 16% growth in specialty chemicals, driven by improved pricing and volume stability. The acquisition of a 40% stake in Zettaone Technologies was announced, aiming to expand into electronics design and manufacturing services. Management guided toward continued growth across all segments in FY27, with expectations of higher volumes from European plant closures and a new multipurpose plant commissioning by year-end. The CDMO business showed strong momentum, with 25+ confirmed molecules in the pipeline. However, challenges included muted pricing in agro-chemicals and some softness in vitamin B3 pricing. Management emphasized strategic investments, including INR400-500 crore annual capex, and expressed confidence in FY27 being a pivotal year for growth.

The document emphasizes strong revenue and EBITDA growth, strategic acquisitions, and confidence in future growth, with management highlighting disciplined execution and expanding opportunities.